Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human PAK4 Protein, N-His

Catalog #:   YHB83501 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: O96013
Protein length: Val299-Ser542
Overview

Catalog No.

YHB83501

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Val299-Ser542

Predicted molecular weight

29.89 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

O96013

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

p21-activated kinase 4, Serine/threonine-protein kinase PAK 4, KIAA1142, PAK-4, PAK4

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human PAK4 protein
References

The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma., PMID:40456026

Design, Synthesis, and Biological Evaluation of Selective PAK4 Degrader for the Treatment of Lung Tumor Metastasis., PMID:40404481

The Role of the p21-Activated Kinase Family in Tumor Immunity., PMID:40332759

Red blood cell-tumor cell interactions promote tumor cell progression., PMID:40301999

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment., PMID:40180890

The role and application of Coronin family in human tumorigenesis and immunomodulation., PMID:40154644

Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies., PMID:40038334

p21-Activated Kinase 4 and Ischemic Acute Kidney Injury in Mice and Humans., PMID:40019790

HSPB1 Orchestrates the Inflammation-Associated Transcriptome Profile of Atherosclerosis in HUVECs., PMID:40018940

The Important Role of p21-Activated Kinases in Pancreatic Exocrine Function., PMID:40001881

PAK4 promotes the cytoskeletal organization and meiotic maturation via phosphorylating DDX17 in oocyte., PMID:39948582

Transketolase promotes osteosarcoma progression through the YY1-PAK4 axis., PMID:39853945

Identification of Potential Selective PAK4 Inhibitors Through Shape and Protein Conformation Ensemble Screening and Electrostatic-Surface-Matching Optimization., PMID:39852144

Glioblastoma-derived migrasomes promote migration and invasion by releasing PAK4 and LAMA4., PMID:39833606

Quantum DFT analysis and molecular docking investigation of various potential breast cancer drugs., PMID:39545283

KGF secreted from HSCs activates PAK4/BMI1, promotes HCC stemness through PI3K/AKT pathway., PMID:39544166

PAK4 is Required for Meiotic Resumption, Spindle Assembly, and Cortical Migration in Mouse Oocytes During Meiotic Maturation., PMID:39435597

Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4-(4-methylpiperazin-1-yl)phenyl scaffold as potential antitumor agents., PMID:39427518

Inhibition of NAMPT by PAK4 Inhibitors., PMID:39337621

Remifentanil-induced inflammation in microglial cells: Activation of the PAK4-mediated NF-κB/NLRP3 pathway and onset of hyperalgesia., PMID:39322089

PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients., PMID:39273017

Targeting RAC1 reactivates pyroptosis to reverse paclitaxel resistance in ovarian cancer by suppressing P21-activated kinase 4., PMID:39224538

Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS/MS Analysis and Immunohistochemical Validation., PMID:39199615

PAK4 phosphorylates and inhibits AMPKα to control glucose uptake., PMID:39127697

Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via FOXA1 Inhibition., PMID:39000600

PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?, PMID:38924842

Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia., PMID:38916832

PAK4 inhibition augments anti-tumour effect by immunomodulation in oral squamous cell carcinoma., PMID:38890401

A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction., PMID:38885414

TBC1D10B promotes tumor progression in colon cancer via PAK4‑mediated promotion of the PI3K/AKT/mTOR pathway., PMID:38824479

Multi-modal mechanisms of the metastasis suppressor, NDRG1: Inhibition of WNT/β-catenin signaling by stabilization of protein kinase Cα., PMID:38815861

Development of a PAK4-targeting PROTAC for renal carcinoma therapy: concurrent inhibition of cancer cell proliferation and enhancement of immune cell response., PMID:38810561

Tumorigenic role of Pak4 in ovarian cancer and its correlation with immune infiltration., PMID:38807162

Inhibition of P21-activated kinases 1 and 4 synergistically suppresses the growth of pancreatic cancer by stimulating anti-tumour immunity., PMID:38797819

Retracted: Interfering with pak4 Protein Expression Affects Osteosarcoma Cell Proliferation and Migration., PMID:38549986

Synthesis of novel (R)-carvone-tagged thiazolidinone as anticancer leads: characterization, in vitro antiproliferative evaluation and in silico studies., PMID:38523573

Interaction between p21-activated kinase 4 and β-catenin as a novel pathway for PTH-dependent osteoblast activation., PMID:38497504

Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer., PMID:38424218

Identification of P21 (CDKN1A) Activated Kinase 4 as a Susceptibility Gene for Familial Non-Medullary Thyroid Carcinoma., PMID:38411500

p21-activated kinase 4 counteracts PKA-dependent lipolysis by phosphorylating FABP4 and HSL., PMID:38216738

Different Transcriptome Features of Peripheral Blood Mononuclear Cells in Non-Emphysematous Chronic Obstructive Pulmonary Disease., PMID:38203236

Molecular cartography uncovers evolutionary and microenvironmental dynamics in sporadic colorectal tumors., PMID:38065082

Design, synthesis and anticancer activity evaluation of 4-(3-1H-indazolyl)amino quinazoline derivatives as PAK4 inhibitors., PMID:37864885

PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways., PMID:37720313

Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers., PMID:37703579

miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway., PMID:37611431

p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1., PMID:37591884

Cofilin activation in pancreatic acinar cells plays a pivotal convergent role for mediating CCK-stimulated enzyme secretion and growth., PMID:37138671

PAK4-relevant proliferation reduced by cell autophagy via p53/mTOR/p-AKT signaling., PMID:37033362

Baicalein Inhibits the Growth of Transplanted Esophageal Cancer in Mice and the Effect on the Expression of PAK4., PMID:36899200

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human PAK4 Protein, N-His [YHB83501]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only